ThyroidNCT02776969
A Gene Hunting Study for Familial Papillary Thyroid Cancer
An observational study of Thyroid, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
Trial summary
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thyroid
- How many people
- 1,200 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Aug 1998to 9 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Families with at least 4 living individuals with a diagnosis of papillary thyroid carcinoma
Who may be able to join
- Patients with a diagnosis of PTC and a family history of PTC in 3 or more living relatives
- Affected and unaffected family members of the proband*
- For familial cases (families with 4 or more cases of PTC), participation will be offered to all living family members with PTC or benign thyroid disease as well as selected unaffected first and second degree relatives. Participation may also be offered to spouses when needed for analyzing parent/offspring samples.
Who cannot join
- Known germline predisposition (ex: pathogenic PTEN variant)
- Non-English speaking
Trial locations and contacts
1 site in 1 country.
United States1 site
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
About this study
Official title: A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.
Read the detailed description
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). This can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. When possible, linkage analysis on families with multiple individuals affected with PTC may also help identify the putative gene(s).
Study participants will be asked to:
- Complete family history and medical history questionnaires
- Sign a medical record release so that thyroid cancer pathology reports can be obtained
- Supply a blood or saliva sample for genetic studies
- Provide study related information to family members who are needed for family studies
- Conditions
- Thyroid
- Keywords
- Papillary Carcinoma, Gene Hunting, Familial
- Medical subject headings
- Thyroid Diseases, Carcinoma, Papillary
What is being measured
The primary outcome is the main question the study is designed to answer.
Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies
Variants will be assessed for segregation within families, expression in the normal thyroid and/or thyroid cancer, and functional significance
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2016 (estimated)
- Study start5 Aug 1998
- Primary completion9 Feb 2025
- Study completion9 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ThyroidStudies of the same condition, open and under way.
- More trials run by Ohio State University Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew Ringel, Ohio State University Comprehensive Cancer Center
- Investigators
- Matthew Ringel, MD, Principal investigator, Ohio State University Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02776969
- Sponsor's protocol ID
- OSU-9812
- Status last verified
- Oct 2026
- First submitted
- 12 May 2016
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated
- ClinicalTrials.gov ID
- NCT02776969
- Acronym / sponsor ID
- OSU-9812
- Conditions
- Thyroid
- Keywords
- Papillary Carcinoma, Gene Hunting, Familial
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Ohio State University Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 5 Aug 1998 (actual)
- Primary completion
- 9 Feb 2025 (actual)
- Study completion
- 9 Feb 2025 (actual)
- First posted
- 19 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.
Detailed description
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). This can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. When possible, linkage analysis on families with multiple individuals affected with PTC may also help identify the putative gene(s).
Study participants will be asked to:
- Complete family history and medical history questionnaires
- Sign a medical record release so that thyroid cancer pathology reports can be obtained
- Supply a blood or saliva sample for genetic studies
- Provide study related information to family members who are needed for family studies
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Families with at least 4 living individuals with a diagnosis of papillary thyroid carcinoma
Key inclusion criteria (3 listed)
- Patients with a diagnosis of PTC and a family history of PTC in 3 or more living relatives
- Affected and unaffected family members of the proband*
Key exclusion criteria (2 listed)
- Known germline predisposition (ex: pathogenic PTEN variant)
- Non-English speaking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies
Time frame: Up to 5 years
Variants will be assessed for segregation within families, expression in the normal thyroid and/or thyroid cancer, and functional significance
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- The JameslineLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Thyroid
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthew Ringel, MD principal investigator
Ohio State University Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid, run by Ohio State University Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.